AB5074P
Anti-Amyloid Antibody, β 1-40
Chemicon®, from rabbit
Sign Into View Organizational & Contract Pricing
All Photos(1)
Anti-AAA, Anti-ABPP, Anti-AD1, Anti-APPI, Anti-CTFgamma, Anti-CVAP, Anti-PN-II, Anti-PN2, Anti-alpha-sAPP, Anti-preA4
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
mouse, human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
immunohistochemistry: suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... APP(351)
General description
The cerebral and vascular plaques associated with Alzheimer′s disease (AD) are mainly composed of amyloid beta peptides (Ab). Ab is derived from cleavage of the amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. Ab [1-40], Ab [1-42], and Ab [1-43] peptides result from cleavage of APP after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last APP processing step. Ab [1-40], [1-42] and [1-43] peptides are major constituents of the plaques and tangles that occur in AD. Ab antibodies and peptides have been developed as tools for elucidating the biology of AD.
Specificity
Recognizes beta-amyloid 1-40. One of the most important and initial steps which causes loss of memory and cognition in Alzheimer′s Disease (AD) involves proteolytic cleavage of amyloid precursor protein (APP, chromosome 21) releasing short 40, 42 & 43 amino acid peptides (beta amyloid 1-40, 1-42 and 1-43). Polymerization of beta-amyloid and subsequent neuronal deposit (amyloid) leads to the degeneration of neurons involved in memory and cognition. The immunogen peptide shows homology with beta-amyloid 1-28 and beta-amyloid 12-28. No cross reactivity is observed with CGRP.
Immunogen
A 7 amino acid peptide sequence from the C terminus of human beta-amyloid 1-40.
Application
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
This Anti-Amyloid Antibody, β 1-40 is validated for use in ELISA, IH, WB for the detection of Amyloid.
Western blot: 1-10 μg/mL (Chemiluminescence technique)
Immunohistochemistry: 10-50 μg/mL using formalin or paraformaldehyde fixed Alzheimer′s brain tissue.
ELISA: 1:10,000-1:100,000 (50-100 ng immunogen peptide/well)
Optimal working dilutions must be determined by the end user.
Immunohistochemistry: 10-50 μg/mL using formalin or paraformaldehyde fixed Alzheimer′s brain tissue.
ELISA: 1:10,000-1:100,000 (50-100 ng immunogen peptide/well)
Optimal working dilutions must be determined by the end user.
Physical form
Affinity Purified immunoglobulin. Liquid in PBS with 0.1% BSA, no preservative.
ImmunoAffinity Purified
Storage and Stability
Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Combined treatment with a BACE inhibitor and anti-A? antibody gantenerumab enhances amyloid reduction in APPLondon mice.
The Journal of Neuroscience null
The Journal of comparative neurology, 521(18), 4318-4338 (2013-07-25)
The two major histopathologic hallmarks of Alzheimer's disease (AD) are amyloid beta protein (Aβ) plaques and neurofibrillary tangles (NFT). Aβ pathology is a common feature in the aged nonhuman primate brain, whereas NFT are found almost exclusively in humans. Few
Journal of neuropathology and experimental neurology, 75(9), 868-876 (2016-07-23)
Tenascin-C (TN-C) is an extracellular matrix glycoprotein linked to inflammatory processes in pathological conditions including Alzheimer disease (AD). We examined the distribution of TN-C immunoreactivity (ir) in relation to amyloid-β (Aβ) plaques and vascular Aβ deposits in autopsy brain tissues
Dendritic spine density, morphology, and fibrillar actin content surrounding amyloid-? plaques in a mouse model of amyloid-? deposition.
Journal of Neuropathology and Experimental Neurology null
Human pathology, 64, 191-197 (2017-02-06)
Amyloid-β-related angiitis (ABRA) is a rare complication of cerebral amyloid angiopathy in which amyloid-β deposition in the leptomeningeal and cortical vessels is associated with vasculitis characterized by transmural lymphohistiocytic, often granulomatous, inflammation. Patients usually present with acute to subacute cognitive
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service